BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao Y, Chen X, He C, Gao G, Chen Z, Du J. Discovery of bilirubin as novel P2X7R antagonist with anti-tumor activity. Bioorg Med Chem Lett 2021;51:128361. [PMID: 34543755 DOI: 10.1016/j.bmcl.2021.128361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Bai X, Li X, Qiao C, Tang Y, Zhao R, Peng X. Progress in the relationship between P2X7R and colorectal cancer. Mol Biol Rep 2022. [DOI: 10.1007/s11033-022-07939-4] [Reference Citation Analysis]
2 Vuerich M, Wang N, Graham JJ, Gao L, Zhang W, Kalbasi A, Zhang L, Csizmadia E, Hristopoulos J, Ma Y, Kokkotou E, Cheifetz AS, Robson SC, Longhi MS. Blockade of PGK1 and ALDOA enhances bilirubin control of Th17 cells in Crohn's disease. Commun Biol 2022;5:994. [PMID: 36131123 DOI: 10.1038/s42003-022-03913-9] [Reference Citation Analysis]
3 Oken AC, Krishnamurthy I, Savage JC, Lisi NE, Godsey MH, Mansoor SE. Molecular Pharmacology of P2X Receptors: Exploring Druggable Domains Revealed by Structural Biology. Front Pharmacol 2022;13:925880. [DOI: 10.3389/fphar.2022.925880] [Reference Citation Analysis]
4 Vultaggio-Poma V, Falzoni S, Salvi G, Giuliani AL, Di Virgilio F. Signalling by extracellular nucleotides in health and disease. Biochim Biophys Acta Mol Cell Res 2022;1869:119237. [PMID: 35150807 DOI: 10.1016/j.bbamcr.2022.119237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]